[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Brandes AA, Cavallo G, Reni M, Tosoni A, Nicolardi L, Scopece L, Franceschi E, Sotti G, Talacchi A, Turazzi S, Ermani M: A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer; 2005 Jul 1;104(1):143-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.
  • BACKGROUND: No data on the role of chemotherapy in recurrent ependymal tumors are available in adults.
  • The aim of the current study was to investigate outcomes after salvage chemotherapy in this setting.
  • METHODS: A retrospective review was made of the charts of 28 adults (> or = 18 years) with progressive or recurrent ependymal tumors after surgery and radiotherapy, who received chemotherapy between 1993 and 2003 in 3 institutions of the Gruppo Italiano Cooperativo di Neuro-Oncologia network.
  • RESULTS: Thirteen patients (46.3%) received cisplatin-based chemotherapy (Group A) and 15 (53.7%) received regimens without cisplatin (Group B).
  • Platinum-based chemotherapy yielded 2 complete responses (CR) (15.4%) and 2 (15.4%) partial responses (PR), whereas 7 patients (53.8%) remained stable (SD).
  • The overall median time to progression was 9.9 months (95% confidence interval [95% CI], 7.5-21.7 months), 9.9 months (5.2-not reached) for Group A and 10.9 months (95% CI, 7.17-23.9 months) for Group B.
  • CONCLUSIONS: Cisplatin-based chemotherapy achieved a higher response rate, but did not prolong disease progression-free survival or OS.
  • More active regimens for the salvage treatment of ependymal tumors have yet to be found.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Ependymoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Italy. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912507.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


2. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P: Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2070-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
  • Our aim was to screen for novel genomic imbalances and prognostic markers in ependymal tumors.
  • EXPERIMENTAL DESIGN: We analyzed 68 sporadic tumors by matrix-based comparative genomic hybridization using DNA microarrays containing >6,400 genomic DNA fragments.
  • Novel recurrent genomic gains were validated by fluorescence in situ hybridization using a tissue microarray consisting of 170 intracranial ependymomas.
  • Candidate genes were also tested for mRNA expression by quantitative real-time PCR, and protein expression was determined by immunohistochemistry on the tissue microarray.
  • RESULTS: Chromosomal gain of 1q correlated with pediatric patients (P = 0.004), intracranial ependymomas (P = 0.05), and tumors of grade III (P = 0.002).
  • Gain of 1q21.1-32.1 was associated with tumor recurrence in intracranial ependymomas (P < 0.001).
  • EGFR protein status subdivides intracranial grade II ependymomas into two different risk groups (P = 0.03) as shown by multivariate analysis.
  • CONCLUSIONS: Thus, the states of 1q25 and EGFR represent independent prognostic markers for intracranial ependymomas to identify patient subgroups with different risk profiles in further clinical investigations.
  • Moreover, EGFR might serve as therapeutic target for more specific chemotherapy applications.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Ependymoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Ependymoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609018.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 9007-49-2 / DNA; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Chamberlain MC, Johnston SK: Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer; 2009 Oct 15;115(20):4775-82
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
  • BACKGROUND: To the authors' knowledge, there currently is no standard therapy for platinum-resistant ependymoma; hence, a need exists for new therapies.
  • In the current study, a retrospective evaluation of temozolomide (TMZ) in adults with recurrent, supratentorial, platinum-refractory, World Health Organization grade 2 ependymoma was performed, with an objective of determining 6-month progression-free survival (PFS).
  • METHODS: A total of 25 patients, ages 28 to 63 years, with recurrent ependymoma were treated.
  • All patients had previously been treated with surgery, radiotherapy, and platinum-based chemotherapy (cisplatin in 15 patients and carboplatin in 10 patients).
  • Patients were treated at the time of second recurrence with TMZ (5 consecutive days), once every 4 weeks, which was defined as a single cycle.
  • One patient (4%) demonstrated a partial radiographic response, 9 (36%) had stable disease, and 15 (60%) developed progressive disease after 2 cycles of TMZ.
  • Time to tumor progression ranged from 1 to 7 months (median, 2 months).
  • CONCLUSIONS: TMZ in this dose schedule demonstrated little efficacy in a cohort of adults with recurrent, intracranial, platinum-refractory ependymoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Ependymoma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Ferrous Compounds. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retreatment

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19569246.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Ferrous Compounds; 33269-57-7 / EX 10-478; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Kumar P, Rastogi N, Jain M, Chhabra P: Extraneural metastases in anaplastic ependymoma. J Cancer Res Ther; 2007 Apr-Jun;3(2):102-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases in anaplastic ependymoma.
  • Ependymoma are rare glial neoplasm, it rarely metastasize outside the central nervous system.
  • We present a case of anaplastic ependymoma with extraneural metastases with review of literature.
  • A ten-year-old male child presented with anaplastic ependymoma of choroid plexus and treated with craniospinal radiotherapy in 1998.
  • He had intracranial recurrence in 2004, confirmed by biopsy.
  • He was given adjuvant chemotherapy in form of PCV.
  • At 10 months after completion of chemotherapy, he developed extracranial scalp metastasis and so was treated with palliative local radiation therapy to the scalp metastasis and systemic chemotherapy with oral Etoposide.
  • After five cycles of chemotherapy, the patient had progression of disease in form of scalp and cervical lymph node metastasis confirmed by fine needle aspiration cytology, biopsy and immunohistochemistry.
  • He was given salvage chemotherapy (carboplatin + ifosfamide + etoposide) at 3-weekly.
  • He had partial response and was still on chemotherapy till May 2007.
  • [MeSH-major] Choroid Plexus Neoplasms / pathology. Ependymoma / secondary. Scalp / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Anaplastic Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998733.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


5. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Delayed toxicity was seen more than 60 days after treatment, with 23 deaths in 100 treated animals, despite a median weight loss of only 0.06%.
  • In mice bearing intracranial D-245 MG xenografts, treatment with VNP40101M at a dose of 18 mg/kg daily for five days produced a 50% increase in median survival compared with controls.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


6. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E: Ependymal tumors in childhood. Pediatr Blood Cancer; 2005 Sep;45(3):298-303
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors in childhood.
  • BACKGROUND: Ependymal tumors are classified as ependymoma (benign or low grade) versus anaplastic ependymoma (malignant or high grade).
  • Ependymomas represent 5-10% of intracranial neoplasm in children.
  • In this study, demographic data and the treatment results of pediatric patients with ependymal tumors, treated in a single institute, is reported.
  • PATIENTS AND METHODS: Between 1989 and 2001, 40 (22 M/18 F) previously untreated patients with a median age of 5.5 years (3 months-15 years), of histologically proven ependymal tumors (except ependymoblastomas) were referred to the Institute of Oncology, University of Istanbul.
  • Total tumor resection was performed in 20 patients (50%), subtotal in 18 patients (45%), and biopsy only in 2 patients (5%).
  • Postoperative treatment consisted of regional (8 patients) or craniospinal (CSI) (9 patients) radiotherapy (RT) in patients with ependymoma; regional (7 patients) or CSI RT (14 patients) with chemotherapy (ChT) in patients with anaplastic ependymoma; ChT only (1 patient) in patients less than 3 years of age.
  • The standard technique for posterior fossa irradiation was parallel-opposed lateral fields and total dose was 45-54 Gy.
  • Median time for progression or relapse was 24.3 months and there were 19 patients (43.6%) with relapse or progression.
  • CONCLUSIONS: The majority of complete responders were patients who had total tumor removal.
  • Treatment failure occurred mainly within the first 2 years, and outcome was dismal for patients who relapsed or had progressive disease.
  • The median age at diagnosis is 6 years in our patient group; younger children (less than 3 years old) have less favorable outcome.
  • [MeSH-major] Brain Neoplasms. Ependymoma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15770637.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Moynihan TJ: Ependymal tumors. Curr Treat Options Oncol; 2003 Dec;4(6):517-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors.
  • Ependymal tumors are rare malignancies that arise from the cells that line the ventricles and central canal of the spinal cord.
  • Although they are more common in children, adults may also be effected by ependymal tumors.
  • Prognosis is dependent on tumor location, histology, especially for myxopapillary tumors that tend to occur in the lumbar spine, extent of surgical resection, and stage of disease.
  • Standard therapy consists of complete resection when feasible.
  • Patients with known residual disease may benefit from local radiation therapy, but the extent of radiation field and total dose are controversial.
  • Even in patients treated with involved field radiotherapy, most relapses occur within the original tumor bed, thus local control remains the biggest obstacle to effective therapy.
  • Chemotherapy has little impact against this tumor and has no role in the adjuvant setting, outside of a well designed clinical trial, with the possible exception of children younger than 5 years in an effort to delay radiation.
  • A minority of patients may respond to one of several chemotherapy regimens at the time of recurrence, but the impact of this therapy is limited.
  • Newer treatment strategies are needed.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Ependymoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Emergency Medical Services. Humans. Life Style. Neoplasm Staging. Neurosurgical Procedures. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):532-9 [12671021.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):563-70 [10550587.001]
  • [Cites] Pediatr Neurol. 2001 Feb;24(2):117-21 [11275460.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(2):57-65 [2132926.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):255-68 [12510777.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):295-308 [12078861.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] Med Pediatr Oncol. 1997 Aug;29(2):79-85 [9180907.001]
  • [Cites] Childs Nerv Syst. 1999 Jan;15(1):17-28 [10066016.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):757-61 [11172959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):381-6 [8276653.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] Neurosurgery. 1991 May;28(5):666-71; discussion 671-2 [1876244.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):997-1002 [12209682.001]
  • [Cites] Pediatr Neurosurg. 1996 Jul;25(1):7-12 [9055328.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):135-43 [9524092.001]
  • [Cites] Pediatr Neurosurg. 1998 Jul;29(1):40-5 [9755311.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • (PMID = 14585232.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 28
  •  go-up   go-down


8. Bouffet E, Capra M, Bartels U: Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst; 2009 Oct;25(10):1293-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy for metastatic and recurrent ependymoma of childhood.
  • INTRODUCTION: Chemotherapy has limited role in the up-front management of ependymoma.
  • At the time of recurrence, the role of chemotherapy is also ill defined and the choice of chemotherapeutic agents is often arbitrary, based on anecdotal data and personal experience.
  • METHODS: The purpose of this review is to describe and critically analyze the published literature on chemotherapy in patients with recurrent and metastatic ependymoma.
  • DISCUSSION: The disappointing response rate with single agents (12.9%) and combinations (17.4%) emphasizes the need to re-evaluate the current chemotherapeutic approach of intracranial ependymoma, and biological studies are needed to identify targets that may be considered for clinical trials.
  • [MeSH-major] Ependymoma / drug therapy. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Brain Neoplasms / drug therapy. Child. Humans. Spinal Cord Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):319-23 [3221259.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Sep;27(9):486-90 [16189442.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):19-28 [15072444.001]
  • [Cites] Pediatr Neurol. 2001 Feb;24(2):117-21 [11275460.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4806-12 [17947729.001]
  • [Cites] J Neurooncol. 1987;5(3):241-4 [3681386.001]
  • [Cites] Neuro Oncol. 2003 Oct;5(4):261-7 [14565163.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6712-8 [18006772.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):249-56 [1732426.001]
  • [Cites] Pediatr Neurosurg. 2002 Jul;37(1):27-31 [12138216.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):516-22 [16428494.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2762-7 [7743483.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):30-6 [16047361.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):287-99 [16195801.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 May-Jun;19(3):187-91 [9201138.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3137-43 [17634493.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):41-4 [10695820.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81 [11464982.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1219-23 [18425379.001]
  • [Cites] J Neurooncol. 1991 Aug;11(1):57-63 [1919647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1129-35 [18797459.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23 (30):7646-53 [16234526.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):919-24 [18281665.001]
  • [Cites] Pediatr Neurol. 1998 Jan;18(1):23-9 [9492087.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):50-5 [15768380.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1522-8 [16575002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):929-35 [11429220.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • [Cites] J Neurooncol. 1983;1(1):45-8 [6678305.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2420-3 [2555038.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):618-24 [8814165.001]
  • [Cites] Childs Nerv Syst. 2005 Mar;21(3):230-3 [15338180.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):34-40 [16874765.001]
  • [Cites] Acta Cytol. 1964 Mar-Apr;8(2):141-9 [4169713.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):557-63 [2364367.001]
  • [Cites] J Neurooncol. 1986;3(4):341-2 [3958779.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14 ):2335-42 [16899365.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):758-60 [16261561.001]
  • [Cites] J Neurosurg. 1984 Dec;61(6):1063-8 [6502234.001]
  • [Cites] Med Pediatr Oncol. 1997 Jul;29(1):28-32 [9142202.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):62-6 [2826716.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1294-301 [12216098.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):169-76 [19065567.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6172-80 [16135484.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Nov-Dec;11(6):1100-3 [2124036.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):3956-62 [10632325.001]
  • [Cites] Pediatr Hematol Oncol. 1999 May-Jun;16(3):245-50 [10326223.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):303-6 [17245619.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):49-53 [8381203.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):119-24 [10779024.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):69-76 [2213117.001]
  • [Cites] J Interferon Res. 1988 Dec;8(6):717-25 [3230330.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):67-9 [11466729.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Childs Nerv Syst. 2006 Jul;22(7):652-61 [16565851.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):106-7 [16462515.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):102-8 [11916501.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):87-97 [18406885.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):143-7 [12506183.001]
  • [Cites] Pediatr Neurosurg. 1996 Jul;25(1):7-12 [9055328.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2459-63 [9815647.001]
  • [Cites] J Neurooncol. 1985;3(3):263-9 [3903064.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):135-43 [9524092.001]
  • [Cites] J Neurooncol. 1985;3(2):131-5 [2993536.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):783-8 [2016620.001]
  • [Cites] Pediatr Neurosurg. 1998 May;28(5):273-8 [9732262.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):571-80 [16880787.001]
  • [Cites] Radiology. 1996 Jan;198(1):273-8 [8539393.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] J Neurooncol. 1995;25(1):77-84 [8523093.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):239-47 [14558599.001]
  • [Cites] Invest New Drugs. 1990 Nov;8(4):401-6 [2084075.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):856-60; discussion 860 [9092863.001]
  • (PMID = 19360417.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 85
  •  go-up   go-down


9. Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, Cox T, Chong WK, Campbell RH, Bailey CC, Gattamaneni R, Picton S, Thorpe N, Mallucci C, English MW, Punt JA, Walker DA, Ellison DW, Machin D, Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee: Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol; 2007 Aug;8(8):696-705
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study.
  • BACKGROUND: Over half of childhood intracranial ependymomas occur in children younger than 5 years.
  • As an adjuvant treatment, radiotherapy can be effective, but has the potential to damage the child's developing nervous system at a crucial time-with a resultant reduction in IQ and cognitive impairment, endocrinopathy, and risk of second malignancy.
  • We aimed to assess the role of a primary chemotherapy strategy in avoiding or delaying radiotherapy in children younger than 3 years with intracranial ependymoma.
  • METHODS: Between December, 1992, and April, 2003, we enrolled 89 children with ependymoma who were aged 3 years or younger at diagnosis, of whom nine had metastatic disease on pre-operative imaging.
  • After maximal surgical resection, children received alternating blocks of myelosuppressive and non-myelosuppressive chemotherapy every 14 days for an intended duration of 1 year.
  • Radiotherapy was withheld unless local imaging (ie, from the child's treatment centre) showed progressive disease.
  • There was no significant difference in event-free or overall survival between complete and incomplete surgical resection, nor did survival differ according to histological grade, age at diagnosis, or site of disease.
  • The median time to progression for the 59 patients who progressed was 1.6 years (range 0.1-10.2 years).
  • For the 80 non-metastatic patients, the 23 who achieved the highest relative dose intensity of chemotherapy had the highest post-chemotherapy 5-year overall survival of 76% (95% CI 46.6-91.2), compared with 52% (33.3-68.1) for the 32 patients who achieved the lowest relative dose intensity of chemotherapy.
  • These results suggest, therefore, that primary chemotherapy strategies have an important role in the treatment of very young children with intracranial ependymoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Ependymoma / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Infant. Male. Methotrexate / administration & dosage. Prognosis. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Aug;8(8):665-6 [17679076.001]
  • [CommentIn] Curr Neurol Neurosci Rep. 2009 Mar;9(2):94-6 [19268030.001]
  • [CommentIn] Lancet Oncol. 2007 Sep;8(9):758-9; author reply 760-1 [17765188.001]
  • (PMID = 17644039.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Dallorso S, Dini G, Ladenstein R, Cama A, Milanaccio C, Barra S, Cappelli B, Garrè ML, EBMT-PDWP: Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumours. Bone Marrow Transplant; 2005 Mar;35 Suppl 1:S31-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumours.
  • Primary brain tumours, a heterogeneous group of cancer that constitute the second most common cancer in childhood, were historically treated with neurosurgical resection and radiation therapy.
  • Chemotherapy has proven to be beneficial for some histological types, which has since led to exploration of the role of high-dose chemotherapy and haematopoietic stem cell rescue.
  • Children <3 years at diagnosis carry worse prognosis.
  • Rare cancers such as ependymoblastoma, atypical teratoid rhabdoid tumour and choroid plexus carcinoma have a dismal prognosis regardless of the above-mentioned indicators.
  • The use of myeloablative therapy (MAT) has been investigated to improve the rate of long-term DFS, as well as to reduce and delay in the youngest children the use of the craniospinal irradiation associated with unacceptable late effects.
  • Ependymoma and brain stem tumours, for which the available data discourage the use of MAT, are excluded.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents. Child. Child, Preschool. Female. Humans. Male. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812527.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


11. Lassaletta A, Perez-Olleros P, Scaglione C, Sirvent S, De Prada I, Perez-Martinez A, Ruiz-Hernandez A, Madero L: Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J Neurooncol; 2007 Jul;83(3):303-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child.
  • Ependymoma is the third most common CNS tumor in children.
  • Neuraxis dissemination at the time of diagnosis is rare and occurs in fewer than 10% of patients.
  • Recent advances in neuroimaging, neurosurgery, and radiation therapy have improved disease control and functional outcomes for children with ependymoma.
  • However, children under the age of 3 years with ependymoma and leptomeningeal spread historically have had worse outcomes.
  • It is not clear if age alone, or a combination of risk factors such us unfavorable location, which may prevent gross total resection, and withholding radiation therapy may have contributed to poor outcomes in younger age groups.
  • Therefore, new therapeutic approaches must be attempted.
  • This is a case report of a posterior fossa ependymoma with leptomeningeal dissemination in a two-year-old child, successfully treated with dose intensive chemotherapy and intrathecal liposomal cytarabine.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / drug therapy. Cytarabine / therapeutic use. Ependymoma / drug therapy. Meningeal Neoplasms / drug therapy
  • [MeSH-minor] Child. Drug Administration Routes. Follow-Up Studies. Humans. Injections, Spinal. Liposomes. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2004 Jan;26(1):56-9 [14707716.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):E1214; discussion E1214 [16723873.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):169-73 [16200565.001]
  • [Cites] Childs Nerv Syst. 2005 Oct;21(10):926-9 [15690195.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3916-21 [15459213.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):287-99 [16195801.001]
  • [Cites] Haematologica. 2006 Mar;91(3):ECR02 [16533729.001]
  • [Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):59-64 [16206735.001]
  • [Cites] Ann Pharmacother. 2000 Oct;34(10):1173-8 [11054987.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] Clin Transl Oncol. 2005 Jul;7(6):232-8 [16131445.001]
  • (PMID = 17245619.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


12. Maksoud YA, Hahn YS, Engelhard HH: Intracranial ependymoma. Neurosurg Focus; 2002 Sep 15;13(3):e4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial ependymoma.
  • OBJECT: An intracranial ependymoma is a relatively rare but very interesting variety of glioma.
  • In this paper, the authors compiled a review of the pathological features, imaging characteristics, and treatment strategies related to this brain tumor.
  • METHODS: A Medline search was conducted using the term "ependymoma."
  • The bibliographies of papers obtained were also checked for articles and chapters that could provide additional understanding of this tumor.
  • CONCLUSIONS: The posterior fossa is the most frequent site for an intracranial ependymoma.
  • Most authors recommend resecting as much of the tumor as is safely possible.
  • Microscopically, ependymal tumors show both epithelial and glial features.
  • Because ependymomas often recur despite surgical intervention, radiotherapy and/or radiosurgery may also play an important role in their treatment.
  • The use of chemotherapy in the treatment of these tumors, especially in the very young, is still being studied.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Ependymoma / pathology. Ependymoma / surgery

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844876.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


13. Kano H, Niranjan A, Kondziolka D, Flickinger JC, Lunsford LD: Outcome predictors for intracranial ependymoma radiosurgery. Neurosurgery; 2009 Feb;64(2):279-87; discussion 287-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome predictors for intracranial ependymoma radiosurgery.
  • OBJECTIVE: To develop outcome predictors after stereotactic radiosurgery (SRS) in patients with intracranial ependymomas who had received previous fractionated radiation therapy, we compared tumor control, survival, and complications with tumor grade, volume, age of patients, and imaging characteristics.
  • METHODS: We retrospectively reviewed records of 39 consecutive ependymoma patients who underwent SRS for 56 tumors.
  • All patients had previous surgical resection of their ependymomas followed by radiotherapy, and 14 patients underwent previous chemotherapy.
  • Twenty-five patients had low-grade ependymomas (34 tumors), and 14 patients had anaplastic ependymomas (22 tumors).
  • The median radiosurgery target volume was 3.6 cm (range, 0.1-36.8 cm), and the median margin dose was 15.0 Gy (range, 10-22 Gy).
  • Lower histological tumor grade was not significantly associated with better progression-free survival (P = 0.725).
  • Factors associated with an improved progression-free survival included smaller tumor volume and homogeneous tumor contrast enhancement in low-grade ependymomas.
  • CONCLUSION: SRS provides another management option for patients with residual or recurrent ependymomas that have failed surgery and radiation therapy.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / surgery. Ependymoma / epidemiology. Ependymoma / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Outcome Assessment (Health Care) / methods. Radiosurgery / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Pennsylvania / epidemiology. Retrospective Studies. Risk Assessment / methods. Risk Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190457.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. El-Gaidi MA, Eissa EM: Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center. Pediatr Neurosurg; 2010;46(4):272-82
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center.
  • OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common neoplasm in infants.
  • RESULTS: Out of 451 patients with primary intracranial neoplasms (age 0-14 years), 21 infants (<1 year) underwent surgery, representing 4.7% of total cases.
  • The most common tumor was choroid plexus papilloma (23.8%), followed by teratoma (19%) then astrocytoma and ependymoma (14.3% each).
  • Three patients received chemotherapy, but none received radiotherapy.
  • The statistically significant predictors of prognosis were the extent of resection and tumor grade.
  • CONCLUSION: Although the prognosis for infantile intracranial neoplasms is worse than for older children, an overall promising outcome with low operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant chemotherapy as part of a multidisciplinary approach.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Papilloma, Choroid Plexus / mortality. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21160236.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, Sainte-Rose C, Zerah M, Thorne J, Renier D: Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg; 2002 Oct;97(4):827-35
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy.
  • OBJECT: The aim of this study was to investigate the effect of patient-related factors, extent of surgery, and adjuvant therapy on survival in children presenting with intracranial ependymoma.
  • METHODS: Between 1980 and 1999, 83 children (mean age 36 months) underwent surgery for intracranial ependymomas.
  • Complete resection, verified on postoperative computerized tomography scans, was achieved in 73%.
  • Adjuvant therapy modalities have changed over the years: before 1990 all patients received radiotherapy, whereas after 1990 the children younger than 3 years of age and later those younger than 5 years of age were treated first with chemotherapy and received radiotherapy only after their first tumor recurrence.
  • The patients in the chemotherapy group did not fare as well as those in the radiotherapy group.
  • A subgroup (36%) within the chemotherapy group, however, survived tumor free after a mean follow-up period of 67 months.
  • It is not clear whether this subgroup either responded well to chemotherapy or needed no adjuvant therapy.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / therapy. Ependymoma / surgery. Ependymoma / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Child, Preschool. Disease-Free Survival. Educational Status. Female. Follow-Up Studies. Fourth Ventricle. Humans. Hydrocephalus / mortality. Hydrocephalus / surgery. Hydrocephalus / therapy. Infant. Intelligence Tests. Male. Neoplasm Recurrence, Local. Postoperative Complications / mortality. Prognosis. Radiotherapy. Survival Analysis

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12405370.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Chamberlain MC: Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol; 2001 Feb;24(2):117-21
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide.
  • Chronic oral VP-16 (etoposide) is a chemotherapy regimen with a wide application in oncology and documented efficacy against germ cell tumors, lymphomas, Kaposi's sarcoma, and primary brain tumors.
  • This study was performed to assess the toxicity and activity of chronic oral etoposide in the management of children with recurrent intracranial nondisseminated ependymoma.
  • Twelve children (median age of 8 years) with recurrent ependymoma who were refractory to surgery, radiotherapy, and chemotherapy (carboplatinum or the combination of procarbazine, lomustine, and vincristine) were treated with chronic oral etoposide (50 mg/m(2)/day).
  • Treatment-related complications included the following: alopecia (10 children), diarrhea (6), weight loss (5), anemia (4), neutropenia (3), and thrombocytopenia (3).
  • Three children required transfusion (two with packed red blood cells; two with platelets), and two children developed neutropenic fever.
  • No treatment-related deaths occurred.
  • In this small cohort of children with recurrent intracranial ependymoma, oral etoposide was well tolerated, produced modest toxicity, and had apparent activity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / drug therapy. Ependymoma / drug therapy. Etoposide / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Male. Neoplasm Recurrence, Local. Prospective Studies. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11275460.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


17. Kano H, Yang HC, Kondziolka D, Niranjan A, Arai Y, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. J Neurosurg Pediatr; 2010 Nov;6(5):417-23
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas.
  • OBJECT: To evaluate the role of stereotactic radiosurgery (SRS) in patients with recurrent or residual intracranial ependymomas after resection and fractionated radiation therapy (RT), the authors assessed overall survival, distant tumor relapse, progression-free survival (PFS), and complications.
  • METHODS: The authors retrospectively reviewed the records of 21 children with ependymomas who underwent SRS for 32 tumors.
  • All patients underwent resection of an ependymoma followed by cranial or neuraxis (if spinal metastases was confirmed) RT.
  • Eleven patients had adjuvant chemotherapy.
  • Twelve patients had low-grade ependymomas (17 tumors), and 9 patients had anaplastic ependymomas (15 tumors).
  • The median radiosurgical target volume was 2.2 cm(3) (range 0.1-21.4 cm(3)), and the median dose to the tumor margin was 15 Gy (range 9-22 Gy).
  • RESULTS: Follow-up imaging demonstrated therapeutic control in 23 (72%) of 32 tumors at a mean follow-up period of 27.6 months (range 6.1-72.8 months).
  • Factors associated with a longer PFS included patients without spinal metastases (p = 0.033) and tumor volumes < 2.2 cm(3) (median tumor volume 2.2 cm(3), p = 0.029).
  • The distant tumor relapse rate despite RT and SRS was 33.6%, 41.0%, and 80.3% at 1, 2, and 3 years, respectively.
  • Factors associated with a higher rate of distant tumor relapse included patients who had spinal metastases before RT (p = 0.037), a fourth ventricle tumor location (p = 0.002), and an RT to SRS interval < 18 months (p = 0.015).
  • Adverse radiation effects developed in 2 patients (9.5%).
  • Patients with smaller-volume tumors and a later recurrence responded best to radiosurgery.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Disease-Free Survival. Dose Fractionation. Female. Humans. Kaplan-Meier Estimate. Male. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039163.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N: Long-term outcome in patients harboring intracranial ependymoma. J Neurosurg; 2005 Jul;103(1):31-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome in patients harboring intracranial ependymoma.
  • OBJECT: The prognostic significance of tumor grade and resection and the efficacy of prophylactic radiation remain controversial in the management of intracranial ependymoma.
  • The outcomes in patients with intracranial ependymoma treated at the Kyoto University Hospital were reviewed retrospectively, and prognostic significance was analyzed.
  • Eighteen cases involved a Grade II lesion according to the World Health Organization classification of ependymoma and 11 involved a Grade III lesion.
  • Postoperative radiation was applied in 24 cases and chemotherapy was administered in nine.
  • Overall survival and progression-free survival rates were significantly higher in patients with Grade II ependymoma (p = 0.006 and 0.004, respectively) and in patients who had undergone gross-total resection of the tumor (p = 0.002 and 0.04, respectively).
  • Fourteen patients relapsed from 10 to 120 months (median 39 months) after diagnosis.
  • In nine patients the ependymoma recurred only at the original tumor site.
  • All relapses of the Grade II ependymoma initially occurred at the primary tumor site.
  • Histological grade and extent of resection were significantly associated with tumor dissemination (p = 0.0034 and 0.0011, respectively).
  • CONCLUSIONS: Tumor grade and resection are the two important prognostic factors with respect to patient survival, tumor recurrence, and tumor dissemination.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / therapy. Ependymoma / mortality. Ependymoma / therapy. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2006 Sep;105(3):503; author reply 503-4 [16961153.001]
  • [CommentIn] J Neurosurg. 2005 Jul;103(1):4; discussion 4-5 [16121965.001]
  • (PMID = 16121970.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Murakami M, Kuratsu J, Takeshima H, Soyama N, Shinojima N, Ushio Y: Spinal seeding of anaplastic ependymoma mimicking fungal meningitis. A case report and review of the literature. J Neurosurg Sci; 2000 Mar;44(1):46-51; discussion 51-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal seeding of anaplastic ependymoma mimicking fungal meningitis. A case report and review of the literature.
  • BACKGROUND: The spinal seeding from brain tumors sometimes mimicks fungal meningitis on examination of cerebrospinal fluid.
  • METHODS AND RESULTS: A 19-year-old woman gradually developed increased intracranial hypertension.
  • It was totally removed and histologically diagnosed as an anaplastic ependymoma.
  • Radiation- and chemotherapy were administered postoperatively.
  • The patient reported low back pain 5 months after the surgical treatment.
  • MRI disclosed neither spinal dissemination nor tumor recurrence at the primary site.
  • Lumbar puncture was performed and the cerebrospinal fluid (CSF) was found to have an extremely low glucose level (5 mg/dl); no tumor cells were identified.
  • A tentative diagnosis of fungal meningitis was made and anti-fungal therapy was administered transventricularly and transvenously.
  • Sequential CSF studies showed that the glucose level remained extremely low, it even decreased to 0 mg/dl Eight months after the surgical treatment, MRI with Gd-DTPA revealed marked subarachnoid enhancement in both intracranial and spinal areas.
  • An open biopsy was performed and a histological diagnosis of intracranial and spinal seeding of the anaplastic ependymoma was returned.
  • CONCLUSIONS: We report a patient with intracranial and spinal seeding of an anaplastic ependymoma that mimicked fungal meningitis.
  • We discuss the difficulty of obtaining a differential diagnosis in this case and describe the mechanism of the decreased CSF glucose level.
  • [MeSH-major] Ependymoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningitis, Fungal / diagnosis. Neoplasm Seeding


20. Akyüz C, Emir S, Akalan N, Söylemezoğlu F, Kutluk T, Büyükpamukçu M: Intracranial ependymomas in childhood--a retrospective review of sixty-two children. Acta Oncol; 2000;39(1):97-100
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial ependymomas in childhood--a retrospective review of sixty-two children.
  • Tumour sites were in the posterior fossa in 47 patients and supratentorial in 15 patients.
  • Two slightly different types of chemotherapy protocols were applied for an average of one year in 47 patients.
  • Twenty children suffered relapse 4 to 55 months after diagnosis (median 16 months).
  • Sex, histopathologic type, localization of the tumour, extent of surgery, and chemotherapy did not influence the prognosis in our study.
  • Because the majority of recurrences were local, better local tumour control is required.
  • New treatment strategies should be developed in order to improve local control.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10752661.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


21. Grill J, Pascal C, Chantal K: Childhood ependymoma: a systematic review of treatment options and strategies. Paediatr Drugs; 2003;5(8):533-43
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood ependymoma: a systematic review of treatment options and strategies.
  • Childhood intracranial ependymoma have a dismal prognosis, especially in young children and when a gross total resection cannot be performed.
  • Adjuvant therapy is therefore necessary for most, if not all, patients.
  • Despite some indication that benign ependymoma (WHO grade II) could show a better outcome, histology cannot be used at present to stratify treatment protocols.Craniospinal irradiation combined with posterior fossa boost has deleterious adverse effects on cognition.
  • Consequently, pediatric oncology teams have, firstly, tried to use chemotherapy to delay or avoid irradiation, and secondly, progressively reduced irradiation fields to the tumor bed without altering the prognosis.
  • Cisplatin, at a dose of 120 mg/m(2) (cumulated response rate of 34% [95% CI 19-54%]) is the only single agent that has reproducibly shown some efficacy in ependymoma.
  • Despite some combinations showing efficacy in the adjuvant setting, childhood intracranial ependymomas can, in general, be considered as chemoresistant.
  • As the use of chemotherapy with current agents is questionable, phase II studies with new agents and combinations are necessary.
  • In this respect, hyperfractionation or radiosensitizers may be valuable therapeutic options.
  • The treatment of children with ependymoma is a challenge for all caregivers.
  • There is no doubt that any possible improvement in the management of this rare tumor will only be the result of well designed cooperative trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / therapy. Ependymoma / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Drug Resistance, Neoplasm. Drug Therapy, Combination. Humans. Infant. Infant, Newborn. Time Factors

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1988 Dec;6(4):319-23 [3221259.001]
  • [Cites] Cancer Treat Rep. 1982 Dec;66(12 ):2013-20 [6890409.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):889-90 [11416101.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1288-96 [11230470.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):585-9 [10837939.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):117-22 [11943886.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):215-22 [9732252.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] Pediatr Neurosurg. 1996 Jun;24(6):299-305 [8988495.001]
  • [Cites] Radiother Oncol. 1997 Jun;43(3):269-73 [9215786.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):870-5 [10679657.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):563-70 [10550587.001]
  • [Cites] Pediatr Neurol. 2001 Feb;24(2):117-21 [11275460.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):498-505 [10550581.001]
  • [Cites] Childs Brain. 1983;10(3):145-56 [6872622.001]
  • [Cites] Surg Neurol. 2000 Jul;54(1):19-26; discussion 26 [11024503.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] Acta Neurochir (Wien). 1991;111(3-4):96-102 [1950695.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):187-91 [8996518.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3588-9 [11481371.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(2):57-65 [2132926.001]
  • [Cites] J Neurooncol. 1987;5(3):241-4 [3681386.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Mar-Apr;20(2):125-30 [9544162.001]
  • [Cites] Radiat Med. 1994 Nov-Dec;12(6):269-72 [7724818.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23 (2):313-9 [1587752.001]
  • [Cites] Acta Neurochir (Wien). 1990;106(3-4):93-8 [2178314.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;35(2):127-31 [7987988.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):325-32 [11872277.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jul;8(7):1083-113 [6288633.001]
  • [Cites] Pediatr Neurosurg. 1998 Mar;28(3):135-42 [9705591.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):736-41 [2491958.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):249-56 [1732426.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):605-13 [11014538.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2762-7 [7743483.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):210-21 [9440745.001]
  • [Cites] Neurology. 1984 May;34(5):615-9 [6538653.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):41-4 [10695820.001]
  • [Cites] Arch Fr Pediatr. 1988 Apr;45(4):249-54 [3408307.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Pediatr Neurosci. 1988;14 (6):277-85 [3270047.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] Pediatr Neurosurg. 2001 Feb;34(2):77-87 [11287807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Childs Nerv Syst. 1998 Oct;14(10):590-5 [9840385.001]
  • [Cites] Neurosurgery. 1993 Feb;32(2):169-75 [8437653.001]
  • [Cites] Pediatr Neurol. 1996 Apr;14(3):216-19 [8736405.001]
  • [Cites] J Neurooncol. 1987;5(3):217-29 [3316521.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):619-23 [1824685.001]
  • [Cites] Pediatr Neurosurg. 1998 Jun;28(6):314-9 [9782208.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1497-502 [2262372.001]
  • [Cites] Radiother Oncol. 1995 Aug;36(2):101-6 [7501807.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):1981-93 [11597375.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):137-45 [10477017.001]
  • [Cites] J Neurooncol. 1986;3(4):341-2 [3958779.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2766-71 [2025840.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1074-81 [12637473.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):452-6 [8123472.001]
  • [Cites] Med Pediatr Oncol. 1997 Aug;29(2):79-85 [9180907.001]
  • [Cites] Med Pediatr Oncol. 1997 Jul;29(1):28-32 [9142202.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):62-6 [2826716.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):203-11 [10363853.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):813-6 [9708950.001]
  • [Cites] J Neurosurg. 1997 Jun;86(6):943-9 [9171172.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):34-9 [11740805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):757-61 [11172959.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3416-20 [8324751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):381-6 [8276653.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):825-30 [1831193.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):49-53 [8381203.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):69-76 [2213117.001]
  • [Cites] Biochem Pharmacol. 1989 Mar 15;38(6):929-34 [2930593.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] Neuropathol Appl Neurobiol. 1994 Apr;20(2):118-21 [7915406.001]
  • [Cites] Neurosurgery. 1991 May;28(5):666-71; discussion 671-2 [1876244.001]
  • [Cites] Med Pediatr Oncol. 1998;Suppl 1:1-9 [9659940.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Acta Oncol. 1994;33(1):29-32 [8142120.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):102-8 [11916501.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):807-22 [9161731.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 May;55(5):540-8 [8627345.001]
  • [Cites] Pediatr Neurosurg. 1997 Aug;27(2):84-91 [9520080.001]
  • [Cites] Pediatr Neurosurg. 1996 Jul;25(1):7-12 [9055328.001]
  • [Cites] Pediatr Neurosurg. 1996;24(3):119-25 [8870014.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2459-63 [9815647.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] J Neurooncol. 1985;3(3):263-9 [3903064.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):135-43 [9524092.001]
  • [Cites] Pediatr Pathol Lab Med. 1996 Jul-Aug;16(4):551-61 [9025853.001]
  • [Cites] J Neurooncol. 1997 May;32(3):243-52 [9049886.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 [8559293.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):87-98 [8699230.001]
  • [Cites] Pediatr Neurosurg. 1998 May;28(5):273-8 [9732262.001]
  • [Cites] Pediatr Neurosurg. 1998 Jul;29(1):40-5 [9755311.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] Neurosurgery. 1991 May;28(5):659-64; discussion 664-5 [1876243.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] J Neurooncol. 1995;25(1):77-84 [8523093.001]
  • [Cites] J Neurosurg. 1990 Mar;72(3):408-17 [2303876.001]
  • [Cites] Invest New Drugs. 1990 Nov;8(4):401-6 [2084075.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):856-60; discussion 860 [9092863.001]
  • (PMID = 12895136.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 120
  •  go-up   go-down


22. Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet JC, Lena G, Choux M, Pellissier JF: Prognostic factors in intracranial ependymomas in children. J Neurosurg; 2000 Oct;93(4):605-13
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in intracranial ependymomas in children.
  • OBJECT: The occurrence of intracranial ependymomas in children is relatively infrequent, and their prognostic factors are still controversial, especially regarding histological composition.
  • METHODS: A retrospective study was conducted of 37 children treated during the last 20 years for intracranial ependymomas at the Hôpital de la Timone.
  • Both univariate and multivariate statistical analyses were performed to assess the prognostic relevance of patient age and sex, extent of tumor removal, location of the tumor (supratentorial compared with infratentorial, median compared with lateral), tumor histological composition, and adjuvant therapies in affecting the 5-year progression-free survival (PFS) rate and overall survival (OS) rate.
  • In addition, immunohistochemical detection of Ki-67 antigen was performed and the Ki-67 labeling index (LI) evaluated in all cases.
  • The PFS time was shorter in patients younger than 4 years of age and in patients in whom a Ki-67 LI greater than 1 was found (p = 0.03 and 0.006, respectively).
  • Adjuvant radiotherapy and chemotherapy were not relevant to prognosis.
  • Moreover, among the 15 patients in whom total excision was achieved, OS was better in those who did not receive adjuvant therapies.
  • In contrast, adjuvant therapies significantly enhanced PFS time in patients in whom tumor excision was incomplete.
  • CONCLUSIONS: This study and analysis of the literature further highlight that total tumor removal is the treatment of choice for ependymomas in children.
  • Postoperative measurement of residual tumor is required, especially because a subgroup of patients might be treated by surgery alone.
  • Median infratentorial ependymomas have to be distinguished from the lateral type.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Age Factors. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / analysis. Male. Mitotic Index. Neoplasm, Residual. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2000 Oct;93(4):721-3 [11014560.001]
  • (PMID = 11014538.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


23. Jaing TH, Wang HS, Tsay PK, Tseng CK, Jung SM, Lin KL, Lui TN: Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. J Neurooncol; 2004 Jul;68(3):255-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas.
  • The optimal postoperative management of pediatric intracranial ependymomas is controversial.
  • Our retrospective series included 15 with supratentorial and 28 with infratentorial tumors.
  • Radiotherapy was done in 31 patients and chemotherapy in 13.
  • The median survival time was 30 months, and 5-year overall survival and progression-free survival rates were 53.9% and 45.9%, respectively.
  • By tumor site: supratentorial, 56.6% and 50.9%; infratentorial, 52.3% and 42.5%.
  • Twenty-six children relapsed 1-107 months after diagnosis (median: 12 months).
  • Only one of 15 patients with supratentorial tumors developed isolated spinal metastasis.
  • [MeSH-major] Ependymoma / diagnosis. Infratentorial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Supratentorial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2000;39(1):97-100 [10752661.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):117-22 [11943886.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):215-22 [9732252.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):52-7 [12007941.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23 (2):313-9 [1587752.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):295-308 [12078861.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):605-13 [11014538.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):51-7 [9874186.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):83-91 [2105621.001]
  • [Cites] Pediatr Neurosurg. 2001 Feb;34(2):77-87 [11287807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Pediatr Neurol. 1996 Apr;14(3):216-19 [8736405.001]
  • [Cites] Childs Nerv Syst. 2001 Feb;17(3):121-33 [11305764.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):193-9 [12691623.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):629-42, 644; discussion 645-6, 648 [12108890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):381-6 [8276653.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):11-8 [9990108.001]
  • [Cites] Childs Nerv Syst. 2000 Mar;16(3):170-5 [10804053.001]
  • [Cites] Paediatr Drugs. 2003;5(8):533-43 [12895136.001]
  • (PMID = 15332330.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust P, Stockhammer F, Röttgen R, Gutberlet M, Ruf J, Felix R: Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology; 2005 Jan;47(1):18-26
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.
  • The value of single-photon emission tomography (SPECT) using iodine-123-alpha-methyl-tyrosine (IMT) for the diagnosis of recurrent or residual gliomas is well established.
  • In the current study we investigated whether IMT-SPECT could also be useful in the follow-up of brain metastases and other intracranial tumours of non-astrocytic origin.
  • The study included 22 patients with suspected recurrent intracranial tumours of non-astrocytic origin (12 brain metastases, one supratentorial primitive neuroendocrine tumour (PNET), one rhabdoid tumour, two clivus chordomas, three ependymomas, two pituitary tumours, one anaplastic meningioma) who had previously been treated by surgery and/or radio/chemotherapy.
  • We concluded that the IMT-SPECT is a promising complementary imaging tool for the detection of recurrences of non-astrocytic intracranial tumours and their distinguishing from treatment-induced changes.
  • The limitation of the IMT-SPECT is its low sensitivity for the detection of small lesions.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Iodine Radioisotopes. Methyltyrosines. Neoplasm Recurrence, Local / diagnostic imaging. Radiopharmaceuticals. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Chordoma / diagnostic imaging. Ependymoma / diagnostic imaging. False Negative Reactions. False Positive Reactions. Female. Follow-Up Studies. Glioma / diagnostic imaging. Humans. Magnetic Resonance Imaging. Male. Meningioma / diagnostic imaging. Middle Aged. Neuroendocrine Tumors / diagnostic imaging. Pituitary Neoplasms / diagnostic imaging. Retrospective Studies. Rhabdoid Tumor / diagnostic imaging. Sensitivity and Specificity. Supratentorial Neoplasms / diagnostic imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2001 Apr;42(4):579-85 [11337545.001]
  • [Cites] Acta Radiol. 1989 Mar-Apr;30(2):121-8 [2493795.001]
  • [Cites] Ann Nucl Med. 2002 Nov;16(7):503-6 [12508845.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):49-58 [15527107.001]
  • [Cites] AJR Am J Roentgenol. 1994 Dec;163(6):1459-65 [7992747.001]
  • [Cites] Eur J Nucl Med. 1998 Feb;25(2):177-81 [9473267.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1793-800 [11079485.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):801-19 [10517946.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):396-404 [11786566.001]
  • [Cites] Eur J Nucl Med. 1999 Feb;26(2):144-51 [9933348.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):162-71 [8153662.001]
  • [Cites] Nuklearmedizin. 1995 Apr;34(2):71-5 [7761277.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] J Nucl Med. 1989 Jan;30(1):110-2 [2783455.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10 ):1736-43 [9776279.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):23-7 [9443732.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14 (3):524-7 [8517335.001]
  • [Cites] Nucl Med Commun. 1996 Mar;17 (3):197-8 [8692485.001]
  • [Cites] J Nucl Med. 1997 Apr;38(4):517-22 [9098193.001]
  • [Cites] Radiology. 1993 Jan;186(1):37-44 [8416584.001]
  • [Cites] Acta Radiol. 1990 Sep;31(5):417-29 [2261284.001]
  • [Cites] Radiology. 2003 Jan;226(1):181-7 [12511688.001]
  • [Cites] Nuklearmedizin. 1997 Mar;36(2):36-41 [9148271.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):374-81 [15001676.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):28-33 [8355844.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] Curr Opin Oncol. 1994 May;6(3):254-61 [8080854.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):579-86 [15073253.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54 [12377338.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2252-9 [10873075.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] Nucl Med Commun. 1996 Jul;17 (7):609-15 [8843121.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Nuklearmedizin. 2002;41(4):191-6 [12224403.001]
  • [Cites] Ann Neurol. 1991 Apr;29(4):347-55 [1929205.001]
  • [Cites] J Nucl Med. 1990 Mar;31(3):281-6 [2155314.001]
  • (PMID = 15630586.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 0 / Radiopharmaceuticals; A77N8J5H5T / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


25. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R: Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol; 2001 Jun-Jul;23(5):277-81
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
  • PURPOSE: To assess the efficacy and define the toxicity of paclitaxel given at a dosage of 350 mg/m2 every 3 weeks as a 24-hour continuous infusion to children with recurrent or progressive primary brain tumors.
  • PATIENTS AND METHODS: Seventy-three eligible patients, ages 4 months to 19 years, with progressive or recurrent primary brain tumors were treated according to a Pediatric Oncology Group (POG) phase II protocol with paclitaxel (POG 9330).
  • Tumor histologic strata included: astrocytoma (n = 4), malignant glioma (n = 13), medulloblastoma (n = 16), brain stem glioma (n = 15), ependymoma (n = 13), and miscellaneous histologies (n = 12).
  • All patients had previous histologic confirmation of a primary intracranial or spinal cord tumor with magnetic resonance imaging or computed tomography documentation of unequivocally measurable progressive or recurrent disease.
  • All patients had received previous therapy including surgery, radiation therapy, and/or chemotherapy, but no patient had been previously treated on more than one phase II trial.
  • Patients were allowed to continue therapy for a total of 18 cycles in the absence of progressive disease or unacceptable toxicity.
  • RESULTS: Seventy-five patients were enrolled onto the POG 9330 protocol; two ineligible patients were removed from the study before receiving any therapy.
  • CONCLUSION: Paclitaxel is well tolerated in children with recurrent or progressive brain tumors at this dosage and schedule and may result in short-term disease stabilization in this patient population.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Child, Preschool. Dexamethasone / therapeutic use. Disease Progression. Drug Hypersensitivity / prevention & control. Ependymoma / drug therapy. Ependymoma / pathology. Female. Glioma / drug therapy. Glioma / pathology. Humans. Immunosuppressive Agents / therapeutic use. Infant. Infratentorial Neoplasms / drug therapy. Infratentorial Neoplasms / pathology. Infusions, Intravenous. Male. Medulloblastoma / drug therapy. Medulloblastoma / pathology. Nausea / chemically induced. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Remission Induction. Salvage Therapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464982.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA07431; United States / NCI NIH HHS / CA / CA15525; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Immunosuppressive Agents; 7S5I7G3JQL / Dexamethasone; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Packer RJ: Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children. Curr Neurol Neurosci Rep; 2009 Mar;9(2):94-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children.
  • [MeSH-major] Brain Neoplasms / drug therapy. Ependymoma / drug therapy
  • [MeSH-minor] Child, Preschool. Disease Progression. Disease-Free Survival. Humans. Infant. Neoplasm Metastasis. Postoperative Period

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet Oncol. 2007 Aug;8(8):696-705 [17644039.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):165-77 [18084249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1546-54 [16115736.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):2939-45 [16962317.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):203-11 [10363853.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):432-41 [17559078.001]
  • (PMID = 19268030.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Rehman S, Brock C, Newlands ES: A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy. Am J Clin Oncol; 2006 Feb;29(1):106-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Ependymoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Time Factors

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462515.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down






Advertisement